ZVRA Latest News, Press Relases and Analysis

All

Press Releases

5 days ago - By: Zevra Therapeutics

Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhD

17 days ago - By: Zevra Therapeutics

Zevra Therapeutics, Inc. Announces CFO Transition

a month ago - By: The Motley Fool

Zevra (ZVRA) Q3 2025 Earnings Call Transcript

a month ago - By: Zacks Investment Research - Mentions: AKBA

Zevra Therapeutics (ZVRA) Reports Q3 Loss, Lags Revenue Estimates

a month ago - By: Zevra Therapeutics

Zevra Reports Third Quarter 2025 Financial Results and Corporate Update

a month ago - By: Benzinga - Mentions: TECH INSE GEF SKYT ...

Earnings Scheduled For November 5, 2025

4 months ago - By: Benzinga

A Look at Zevra Therapeutics's Upcoming Earnings Report

a month ago - By: Zevra Therapeutics

Zevra Therapeutics to Participate in the Guggenheim Healthcare Innovation Conference

a month ago - By: Zevra Therapeutics

Zevra Therapeutics Announces Details for Q3 2025 Financial Results Call

2 months ago - By: Zevra Therapeutics

Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: Zevra Therapeutics

Zevra Therapeutics Announces Upcoming Oral Presentation at the International Niemann-Pick Disease Alliance (INPDA) Meeting and Poster Presentations at the Child Neurology Society (CNS) Conference on MIPLYFFA® (arimoclomol) and OLPRUVA® (sodium

3 months ago - By: Zevra Therapeutics

Zevra Therapeutics Presents Positive New Data Supporting Foundational Role of MIPLYFFA® (arimoclomol) for the Treatment of Niemann-Pick Disease Type C at the International Congress of Inborn Errors of Metabolism (ICIEM)

3 months ago - By: Zevra Therapeutics

Zevra Therapeutics Announces Multiple Datasets on MIPLYFFA® (arimoclomol) to be Presented at the International Congress of Inborn Errors of Metabolism (ICIEM)

3 months ago - By: Zevra Therapeutics

Zevra Therapeutics to Participate at Upcoming Investor Conferences in September

4 months ago - By: Zacks Investment Research - Mentions: PROF

Zevra Therapeutics (ZVRA) Reports Q2 Loss, Tops Revenue Estimates (Revised)

4 months ago - By: Investor's Business Daily - Mentions: AMGN

Zevra Reported Its First-Ever Quarterly Profit. Why Shares Of The Top 6% Stock Crashed.

4 months ago - By: The Motley Fool

Zevra Revenue Jumps 486 Percent in Q2

4 months ago - By: Zacks Investment Research - Mentions: PROF

Zevra Therapeutics (ZVRA) Reports Q2 Loss, Tops Revenue Estimates

4 months ago - By: Zevra Therapeutics

Zevra Reports Second Quarter 2025 Financial Results and Corporate Update

4 months ago - By: Zacks Investment Research - Mentions: GILD INO DERM

3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

4 months ago - By: Zacks Investment Research

What Makes Zevra Therapeutics (ZVRA) a Good Fit for 'Trend Investing'

4 months ago - By: Zevra Therapeutics

Zevra Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference

4 months ago - By: Zacks Investment Research - Mentions: COLL

Zevra Therapeutics (ZVRA) Reports Next Week: Wall Street Expects Earnings Growth

4 months ago - By: Zevra Therapeutics

Zevra Therapeutics Announces Details for Q2 2025 Financial Results Call

4 months ago - By: Zevra Therapeutics

Zevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C

5 months ago - By: Zevra Therapeutics

ZEVRA THERAPEUTICS INC (ZVRA) Stock News

ZVRA Latest News, Press Relases and Analysis

Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhD

Zevra Therapeutics, Inc. Announces CFO Transition

Zevra (ZVRA) Q3 2025 Earnings Call Transcript

Zevra Therapeutics (ZVRA) Reports Q3 Loss, Lags Revenue Estimates

Zevra Reports Third Quarter 2025 Financial Results and Corporate Update

Earnings Scheduled For November 5, 2025

A Look at Zevra Therapeutics's Upcoming Earnings Report

Zevra Therapeutics to Participate in the Guggenheim Healthcare Innovation Conference

Zevra Therapeutics Announces Details for Q3 2025 Financial Results Call

Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Zevra Therapeutics Announces Upcoming Oral Presentation at the International Niemann-Pick Disease Alliance (INPDA) Meeting and Poster Presentations at the Child Neurology Society (CNS) Conference on MIPLYFFA® (arimoclomol) and OLPRUVA® (sodium

Zevra Therapeutics Presents Positive New Data Supporting Foundational Role of MIPLYFFA® (arimoclomol) for the Treatment of Niemann-Pick Disease Type C at the International Congress of Inborn Errors of Metabolism (ICIEM)

Zevra Therapeutics Announces Multiple Datasets on MIPLYFFA® (arimoclomol) to be Presented at the International Congress of Inborn Errors of Metabolism (ICIEM)

Zevra Therapeutics to Participate at Upcoming Investor Conferences in September

Zevra Therapeutics (ZVRA) Reports Q2 Loss, Tops Revenue Estimates (Revised)

Zevra Reported Its First-Ever Quarterly Profit. Why Shares Of The Top 6% Stock Crashed.

Zevra Revenue Jumps 486 Percent in Q2

Zevra Therapeutics (ZVRA) Reports Q2 Loss, Tops Revenue Estimates

Zevra Reports Second Quarter 2025 Financial Results and Corporate Update

3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

What Makes Zevra Therapeutics (ZVRA) a Good Fit for 'Trend Investing'

Zevra Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference

Zevra Therapeutics (ZVRA) Reports Next Week: Wall Street Expects Earnings Growth

Zevra Therapeutics Announces Details for Q2 2025 Financial Results Call

Zevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C

Zevra Therapeutics Announces MIPLYFFA® and OLPRUVA® Presentations at the Annual Meeting of the Southeastern Regional Genetics Group (SERGG)